Aptamer biosensor reads sepsis markers at bedside in minutes

New aptamer‑based biosensor can read multiple sepsis markers at the bedside within minutes, cutting the diagnostic window from days to hours. Sepsis, which kills 11 million people annually, currently relies on blood tests that may take up to 48 hours. The reported platform uses synthetic DNA/RNA aptamers to capture immune proteins and a gold‑silver alloy nanostructure that amplifies the signal, while a machine‑learning system interprets complex patterns to confirm infection and stage severity. The device is compact enough to sit beside a patient’s bed, offering real‑time results. The technology builds on six decades of biosensor research, from the 1962 glucose electrode invented by Leland C. Clark, Jr. and Champ Lyons to modern nanomaterials such as gold nanoparticles, carbon nanotubes, graphene and MXenes that increase surface area and electrical response. Aptamers have replaced antibodies because they are cheaper, more stable and can be produced entirely in the lab. Over the past 20 years scientists have created aptamers for hundreds of disease‑relevant proteins, making them the preferred recognition element in advanced sensors. Beyond sepsis, similar platforms are being trialled for early pancreatic‑cancer detection, wearable microneedle patches that sample skin proteins, and cell‑free sensors that test water for heavy metals. Researchers are also linking CRISPR enzymes to aptamers for rapid detection of malaria, SARS‑CoV‑2 and cancer biomarkers. The next frontier is closed‑loop systems that use AI to trigger drug delivery based on real‑time protein data, though hurdles such as sensor stability, individual baseline variation and regulatory approval remain.

Context

Rapid protein biosensing leverages the fact that protein levels change before symptoms appear, allowing clinicians to intervene earlier and improve patient outcomes.